• NaomiPearce

Eylea® | Aflibercept | Regeneron

30 Oct 20 | CN | Ocumension, Shandong Boan Biological Technology | Ocumension Therapeutics announces it has reached an agreement with Shandong Boan Biological Technology to jointly develop OT-702, a proposed aflibercept biosimilar. Under the agreement, Ocumension has been granted an exclusive license to promote and commercialise the product in mainland China. OT-702 is currently in Ph III trials.

30 Jun 2020 | All | Samsung Bioepis | Samsung Bioepis announces it has commenced Ph III trials of SB15, proposed aflibercept biosimilar.

15 Jun 2020 | All | Samsung Bioepis | Samsung Bioepis announces it has received approval to commence a global Ph III trial of SB15 (proposed aflibercept biosimilar) in patients with age-related macular degeneration.

15 May 2020 | All | Formycon | Formycon releases an update on its biosimilar portfolio, announcing its biosimilar aflibercept candidate is proceeding as expected, with Ph III clinical trials expected to begin mid-2020.

06 Nov 2019 | All | Biogen, Samsung Bioepis | Biogen and Samsung Bioepis announce partnership for the commercialisation of biosimilars ranibizumab and aflibercept. The agreement covers the US, Canada, Europe, Japan and Australia. Under the agreement, Biogen will make one $100M upfront payment, with up to $210M payable at additional development, regulatory and sales-based milestones.

03 Nov 2019 | All | Gene Techno Science, Kishi Kasei | Gene Techno Science and Kishi Kasei announce agreement for the joint development of an aflibercept biosimilar.

12 Oct 2019 | All | Alteogen | Alteogen announces Phase I clinical trials of biosimilar aflibercept candidate will begin this month.

13 Aug 2019 | US | Regeneron | Regeneron announces FDA approval for Eylea in 2mg, single dose prefilled syringe. The product is expected to launch this year and will require fewer preparation steps in comparison to the previously approved vials.

22 Feb 2019 | KR | Alteogen | Alteogen announces new drug application to the Ministry of Food and Drug Safety for aflibercept biosimilar, ALT-L9.

07 Jan 2019 | US | Regeneron | Regeneron announces $4.07 billion in 2018 US net sales for Eylea®, as it awaits the commencement of new clinical trials for a high dose formulation. Additionally, the FDA has assigned 13 May 19 as the action date for a potential new indication in diabetic retinopathy.

04 Jan 2019 | All | Alteogen | Alteogen announces it has been granted a process patent for producing aflibercept biosimilar, ALT-L9. Alteogen reports the process improves the productivity and quality of large-scale production of fusion proteins.

25 Oct 2018 | US | Regeneron | Regeneron announces completion of Phase III clinical trials of Eylea® in patients with moderately severe and severe non-proliferative diabetic retinopathy. The company reported the trial met its one year primary endpoint and key secondary endpoints.

01 Oct 2018 | All | Momenta | Momenta announces a shift in focus from biosimilars to novel therapeutics. The 5 year re-structuring plan will involve cuts to staff of 50%, however the company will continue to develop biosimilar aflibercept candidate M710.

10 May 2018 | All | Coherus BioSciences | Coherus BioSciences discloses that preclinical studies will be ongoing in 2018 for CHS-2020 biosimilar aflibercept.

17 Jan 2018 | US | Alteogen |Korean Biosimilar company Aleogen announces completion of pre-clinical studies relating to ALT-L9, biosimilar aflibercept, and that it intends to file an investigational NDA with the US in 2018. It also intends to roll out aflibercept in Japan (through partner Kissei Pharmaceutical) and China in 2022 "when the patents of the brand-name drug lapse".

03 Jan 2018 | All | Mylan/Momenta |Mylan and Momenta announce deal relating to the development of M710, biosimilar aflibercept. Pivotal clinical trials are planned for early 2018.

Biosimilars Bulletin 
Search by tags

© 2019 Pearce IP | Australia

  • LinkedIn Social Icon